SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction and highlight its price stability within the Solana ecosystem. Discussions also focus on WAGMI's potential for significant revaluation, drawing comparisons to other successful meme coins like DOGE and SHIB. The community emphasizes WAGMI's organic growth and potential for long-term gains, with some anticipating a major breakout.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential for growth and new projects being built on the platform, including meme coins like $SOLYCAT and $CAW. Community members are also closely watching for potential breakout opportunities, emphasizing the importance of conviction and holding through market volatility. Recent news of Fidelity adding Solana support and institutional validation may be contributing to the positive sentiment.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin "crow with knife" ($CAW) is gaining attention, with community members highlighting its deflationary mechanism and presence across multiple chains like Solana, BSC, CRO, and ETH.  Enthusiasts are also excited about potential staking opportunities and partnerships. Community buzz is focused on its organic growth and strong "cult" following.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as a new Solana-based meme token, generating buzz around its recent launch and availability on Phantom Wallet. The community is drawn to its potential for high gains, with many emphasizing its momentum within the Solana ecosystem alongside established tokens. Conversations highlight its strong chart and potential breakout.

WISeKey International Holding Ltd. is a cybersecurity company, which engages in offering digital security technology solutions. The firm operates through the Internet of Things (IoT), and Managed Public Key Infrastructure (mPKI) segments. The IoT segment refers to the design, manufacturing, sales and distribution of microprocessors operations. The mPKI segment includes all operations relating to the provision of secured access keys, authentication, signing software, certificates and digital security applications. The company was founded by Joao Carlos Creus Moreira and Philippe Doubre in 1999 and is headquartered in Zug, Switzerland.

WISeKey International Holding Ltd - ADR

WISeKey is trending as investors discuss its potential upside in the post-quantum computing era, particularly in securing satellite constellations. The community is highlighting the company's subsidiaries, including SEALCOIN and WISeSat, and comparing its market cap to its parent company, LAES.  Some investors believe WKEY's current valuation doesn't reflect the value of its assets and potential growth in the quantum security market.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions about stablecoin regulation and adoption, with some highlighting its potential role in cross-border payments. Community members are also closely watching partnerships and integrations with various platforms like Binance and Solana. Additionally, there's chatter around meme coins and stablecoin trading strategies, including discussions about the BROKE coin.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community discusses its potential, partnerships, and possible ETF. A segment of the community is focused on the token's multi-chain presence through projects like $CAW. Others express frustration with price action, debating whether to buy and stake or take profits.

Pump.fun

$PUMP is trending as traders discuss its strong community and potential within the Solana ecosystem, with many mentioning $WAGMI and highlighting the token's resilience. Community members are emphasizing holding for the long term and believe the project is coded for success. The conversation includes discussion of potential catalysts and continued building within the $SOL ecosystem.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as the market anticipates the FDA's decision on their supplemental NDA for Revuforj to treat a specific type of leukemia, expected by October 25th. The community is weighing the potential for label expansion and increased market access against existing concerns around boxed warnings and competitor drugs. Some traders believe that approval is already priced in, while others anticipate a significant surge depending on the scope of the label.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to concerns surrounding a recent FDA safety communication regarding allergic reactions to specific lots of its BIVIGAM and ASCENIV products, leading to a stock price drop. While some investors view this as a temporary setback and potential buying opportunity, citing the company's strong financials and growth prospects, others worry about the impact of potential voluntary recalls on revenue and profitability. The community is also discussing the CEO's recent stock sale and speculating about potential short selling or manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know 

Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Biotech stocks, particularly in the small- and mid-cap space, were hot topics among retail investors in 2024, often spurred by major announcements or clinical developments.&nbsp;Collectively, these stocks attracted significant chatter on Stocktwits.&nbsp;Here are the top five biotech stocks with the highest message volume growth this year:Tonix Pharmaceuticals Holding Corp. (TNXP): +47,066% Message VolumeTonix focuses on developing therapies to treat and prevent diseases. Its TNX-102 SL, a non-opioid analgesic for fibromyalgia, gained attention when the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">accepted</a> its New Drug Application in December. Earlier in the year, the company also reiterated its&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">commitment</a> to developing an mpox vaccine. Despite these milestones, TNXP shares are down over 97% this year.Candel Therapeutics Inc. (CADL): +16,000% Message VolumeCandel develops viral immunotherapies targeting cancer. Its lead product, CAN-2409, is under trial for various cancers, including prostate and non-small cell lung cancer. Positive late-stage&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">results</a> released this month for CAN-2409 in prostate cancer drove retail interest. Shares of CADL are up over 500% this year.Cardio Diagnostics Holdings Inc. (CDIO): +11,650% Message VolumeCardio Diagnostics gained traction with its AI-powered PrecisionCHD test for coronary heart disease. The test demonstrated significant cost-saving potential in healthcare, according to the company. Cardio also received final pricing determinations from the Centers for Medicare &amp; Medicaid Services for its products. Its stock has fallen nearly 63% year-to-date.Recursion Pharmaceuticals Inc. (RXRX): +9,600% Message VolumeRecursion uses AI and automation to discover medicines. A $50 million investment from Nvidia to support AI-driven drug discovery efforts primarily sparked significant retail interest this year, although RXRX shares have declined 22% so far in 2024.Galectin Therapeutics Inc. (GALT): +5,800% Message VolumeGalectin’s focus on fibrotic and inflammatory diseases, led by its drug belapectin, caught investors’ attention despite mixed trial results. While the drug didn’t meet statistical significance for a key endpoint in an early liver disease trial, further data analysis is expected in early 2025. GALT shares are down over 48% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

Equity

Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

FY2025 EPS Estimates for Galectin Therapeutics Inc. Lowered by Analyst (NASDAQ:GALT)

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Galectin Therapeutics in a report released on Monday...

Retirement Guys Formula LLC Boosts Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT)

Retirement Guys Formula LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 87.0% during the fourth quarter, according to the company in its most recent 13F...

Galectin Therapeutics (NASDAQ:GALT) Rating Reiterated by HC Wainwright

Galectin Therapeutics (NASDAQ:GALT - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They...

Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments

Comparing GALT's Performance Against Analyst Estimates and Exploring Future ProspectsRelated Stocks: GALT...

Galectin Therapeutics GAAP EPS of -$0.74

Galectin Therapeutics GAAP EPS of -$0.74...

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...

Galectin Therapeutics (NASDAQ:GALT) Lowered to Sell at StockNews.com

StockNews.com downgraded shares of Galectin Therapeutics (NASDAQ:GALT  Free Report) from a hold rating to a sell rating in a research report report published on Monday. Galectin Therapeutics...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.11	--	--	N/A
Q2 '25	-$0.16	-$0.12	25.00%	BEAT
Q1 '25	-$0.20	-$0.15	25.00%	BEAT
Q4 '24	-$0.16	-$0.19	-18.75%	MISSED
Q3 '24	-$0.20	-$0.18	10.00%	BEAT

GALT
Galectin Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest GALT News

GALTGalectin Therapeutics Inc